Eprobemide (LIS 630)
(Synonyms: 依普贝胺,LIS 630) 目录号 : GC30963
Eprobemide is a reversible monoamine oxidase A (MAO-A) inhibitor. Eprobemide acts as an antidepressant in Russia.
Cas No.:87940-60-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Eprobemide is a reversible monoamine oxidase A (MAO-A) inhibitor. Eprobemide acts as an antidepressant in Russia.
[1] Donskaya NS, et al. Pharm Chem J. 2004 Jul;38(7):381-384.
| Cas No. | 87940-60-1 | SDF | |
| 别名 | 依普贝胺,LIS 630 | ||
| Canonical SMILES | O=C(NCCCN1CCOCC1)C2=CC=C(Cl)C=C2 | ||
| 分子式 | C14H19ClN2O2 | 分子量 | 282.77 |
| 溶解度 | DMSO : ≥ 125 mg/mL (442.06 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5364 mL | 17.6822 mL | 35.3644 mL |
| 5 mM | 0.7073 mL | 3.5364 mL | 7.0729 mL |
| 10 mM | 0.3536 mL | 1.7682 mL | 3.5364 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Effect of some benzamide derivatives on stress-induced behavior and striatum dopamine receptors
The effects of a new benzamide derivative LIS-630 and the well-known neuroleptic, tiapride, were studied on stress-induced hyper- and hypoactive emotional behavioral reaction of animals depending on the individual ability for perceptive-cognitive activity in stress situations, and their affinity to striatal DA receptors. A modified variant of forced swimming method was used. The affinity of the substances to striatal DA receptors was studied by the radioligand binding method using 3H-spiroperidol. The results show that the psychopharmacological profile of LIS-630 differs significantly from the neuroleptic, tiapride. LIS-630 restored escape behavior from stress situation after preliminary exposure of rats to forced swimming and did not disturb escape behavior in animals more resistant to emotional hypoactivity. LIS-630 reduced immobility time at forced swimming. However, it is not effective in preventing hyperemotional reactions induced by L-dopa and stress. The radioligand binding study shows that LIS-630 did not displace 3H-spiroperidol from the binding sites of striatum membranes. The parameters of displacement with tiapride were satisfactory.
[Comparative anti-arrhythmia effectiveness of activators of body stress-limiting systems in patients with arrhythmia]
The antiarrhythmic effects produced by activators of the body's stress-limiting systems were comparatively evaluated in patients with cardiac arrhythmias of ischemic and non-ischemic etiology. Acediprol, gidazepam, and befol were found to be beneficial in ventricular premature contraction when psychoemotional stress was simulated, as evidenced by 24-hour monitoring. The most pronounced protective therapeutical effect of the drugs was observed in patients with arrhythmias of extracoronary origin and in individuals with a marked arrhythmogenic effect of stress. Gidazepam was shown to suppress the provocative arrhythmogenic effect of the stress test.
[New pharmacodynamic effects of gidazepam and befol in patients with cardiac arrhythmias]
The new Russian drugs gidazepam, a tranquilizer, and befol, an antidepressant, show not only their psychotropic action, but change cardiac electrophysiological function and produce antiarrhythmic effects, which allows them to be used in the treatment of various cardiac arrhythmias. The antiarrhythmic effect of the psychopharmacological agents is largely shown in patients with ventricular premature contraction and paroxysmal tachycardias in the presence of neurocirculatory dystonia, as well as with great deviations of the electrophysiological properties of the cardiac conduction system from the their mean values, by promoting their normalization. The antiarrhythmic effect of gidazepam is higher than that of befol in both patients with neurocirculatory dystonia and those with coronary heart disease.
[Anti-arrhythmia activity of befol, sufan, mexidol, and T3-146 in combination with other anti-arrhythmia agents]
[A comparative study of befol pharmacokinetics in experimental animals and man]
The pharmacokinetics of befol at different routes of administration to animals and humans was studied. The therapeutic level of the drug concentration was established.